Navigation Links
BioForm Medical Acquires Facial Aesthetic Nerve Ablation Technology
Date:4/30/2008

inimally invasive procedure is conducted in physician's offices with local anesthesia, usually taking approximately 30 minutes. The probe tip is inserted under the skin and the correct nerve is identified through stimulation, which causes visible muscle contraction. The same probe delivers localized and controlled bi-polar RF energy for approximately 30 seconds to reduce nerve function. Commonly reported adverse effects include some pain or discomfort during the treatment, and swelling following the treatment. As with any medical procedure, other adverse outcomes may also occur.

Approximately 300 patients have received nerve ablation treatment with the ACI device worldwide, many in clinical studies intended to support development and evaluation of this device and procedure for aesthetics applications. BioForm Medical intends to further evaluate the ACI device in additional clinical studies worldwide and expects to launch the product commercially upon achieving appropriate regulatory clearances in each market.

Neurotoxin products, such as Botox(R) Cosmetic from Allergan, Inc., are the current leading option for treatment of frown lines. This needle- injection treatment typically provides a short-term (up to four months) effect. Neurotoxins are injected through the skin into the muscle. The neurotoxin keeps the muscle from moving, reducing the appearance of frown lines. Approximately three million treatments per year with Botox Cosmetic are performed in the U.S. annually according to the American Society for Aesthetic Plastic Surgery.

About BioForm Medical, Inc.:

BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California. BioForm is dedicated to bringing doctors and their patients safe and effective products for use in the dermatology, plastic surgery and ENT markets. BioForm's products include Radiesse(R), a long-lasting filler for use in facial aesthetics and vocal fold insufficiency, and Coaptite(R) for
'/>"/>

SOURCE BioForm Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. BioForm Medical to Announce Financial Results For Quarter Ended March 31, 2008, Third Quarter of Fiscal 2008, and Host Conference Call and Webcast on May 1, 2008
2. BioForm Announces Financial Results for Quarter Ended December 31, 2007, Second Quarter of Fiscal 2008
3. BioForm to Announce First Quarter Fiscal 2008 Financial Results and Host Conference Call and Webcast on December 13, 2007
4. ATS Medical Announces First Frontiers in Cryoablation Symposium
5. Medical journal calls upon Barack Obama to do much more
6. ACP hosts largest medical education meeting for general and subspecialty internists
7. Flashpoint Medica Named Agency of Year by Medical Advertising News
8. Virginia Judge Rules Medical Device Pioneer Committed Malpractice
9. Digirad Corporation and University of Chicago Medical Center Sign Letter of Agreement
10. PSI Corp. Announces Additional Hospitals and Medical Office Buildings to Utilize Its Digital Signage Network
11. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... and desires in initial romantic encounters determine the fate ... those initial "sparks" necessary to fuel sexual desire and ... a desirable trait for both men and women on ... the other person? Do men perceive responsive women as ... women,s perceptions of men? A study published in ...
(Date:7/25/2014)... San Mateo, CA (PRWEB) July 25, 2014 ... in an upcoming episode of Innovations with Ed Begley ... Dates and show times TBA. , For more than ... and the Bay Area community through its residential alcohol ... Innovations will educate on Project Ninety's humble idea and ...
(Date:7/25/2014)... July 25, 2014 Home Care Assistance ... provider of non-medical, in-home senior care, is weighing in ... be supporting senior-led projects in Alberta through their New ... for Seniors Program is a federal grants and contributions ... who make a difference in the lives of others ...
(Date:7/25/2014)... Ca (PRWEB) July 25, 2014 The ... with their Anniversary Futon Sale. The Futon Shop has been ... pop shop, which has grown from a few handmade futon ... 33 different kinds of futon mattresses. , The Futon ... the beginning and the desire to sleep on natural fibers ...
(Date:7/25/2014)... ZeptoMetrix™ Corporation (ZMC), an industry leader ... and services for infectious disease diagnostic development, is ... Multimarker Controls - MDZ001 . , An ... marked, unassayed external run control intended for use ... Multimarker Controls - MDZ001 has been specifically designed ...
Breaking Medicine News(10 mins):Health News:Why do men prefer nice women? 2Health News:Why do men prefer nice women? 3Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 3Health News:Home Care Assistance – Halton/Peel Region Weighs in on Alberta Communities Receiving Funding to Support Seniors and Senior Caregivers 2Health News:Home Care Assistance – Halton/Peel Region Weighs in on Alberta Communities Receiving Funding to Support Seniors and Senior Caregivers 3Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 2Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 3Health News:ZeptoMetrix™ Corporation (ZMC) Releases FDA Class 1 Exempt, IVD and CE Labeled NATtrol™ RP Multimarker Controls 2
... protecting children from flu if they included both strains of ... has found. "Adding a second influenza B virus strain ... guesswork out of strain selection and help improve the vaccine,s ... and director of the Center for Vaccine Development at Saint ...
... ... Wigix Inc.’s subsidiary, ddku.com, affording it an end to end marketing platform in China. ... Oakland, CA ... has acquired a Shanghai-based business process outsourcing company, Mag2U, to enhance DDKU’s growing internet ...
... testing, experts say , TUESDAY, April 6 (HealthDay News) -- ... have a genetic mutation that boosts their risk for the ... breast than are women who don,t have the genetic mutations, ... these women, who carry a mutation in the BRCA1 and ...
... Today, the Interactive Autism Network (IAN), www.ianproject.org, the ... of the Grandparents of Children with Autism Spectrum ... who participated were the first to raise concerns ... 2007, the IAN Project has helped to accelerate ...
... Indianapolis, 6 April, 2010 The global nursing shortage is ... schools and to a phenomenon known as nurse migration, where ... response, the International Council of Nurses (ICN) and the Honor ... The Elsevier Foundation, will conduct the Global Summit on Nurse ...
... April 2010 - Attention-deficit/hyperactivity disorder (ADHD) is one of ... adolescents. Children with ADHD are excessively restless, impulsive, and ... Problems inhibiting behavior are a common theme for ADHD ... medications, behavioral approaches or a combination of the two. ...
Cached Medicine News:Health News:Building a better flu vaccine: Add second strain of influenza B 2Health News:Wigix Acquires Mag2U, A Leading Business Process Outsourcing Company 2Health News:Wigix Acquires Mag2U, A Leading Business Process Outsourcing Company 3Health News:Gene Mutations Up Risk for Cancer in Opposite Breast 2Health News:Gene Mutations Up Risk for Cancer in Opposite Breast 3Health News:New survey finds grandparents play key role in lives of children with autism 2Health News:New survey finds grandparents play key role in lives of children with autism 3Health News:International summit seeks solutions to global shortage of nursing faculty 2Health News:Synergy between behavioral and pharmacologic interventions for ADHD 2
(Date:7/24/2014)... July 24, 2014   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ... on the development and commercialization of innovative therapies for ... the PDUFA date for Zalviso remains July 27, 2014.  ... circulated online stating the Food and Drug Administration (FDA) ... has been no notification to the company from the ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
(Date:7/24/2014)... 2014  Uroplasty, Inc. (NASDAQ: UPI ), ... markets innovative proprietary products to treat voiding dysfunctions, ... first quarter ended June 30, 2014.  Global ... System grew 19% to $4.1 million, as compared ... the prior year.  Total revenue for the fiscal ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... Pa., April 23 Wyeth,Pharmaceuticals, a division of ... it,is withdrawing its application for an extension to ... sought approval,of TYGACIL for the treatment of community-acquired ... of the Committee for Medicinal,Products for Human Use ...
... an Investigational Drug for Duchenne/Becker ... Muscular Dystrophy, ... announced the initiation of an international pivotal trial of,PTC124 in patients ... objective of this registration-directed,Phase 2b trial is to demonstrate the efficacy ...
Cached Medicine Technology:More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 2More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 3More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 4More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 5PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 2PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 3PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 4PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 5
The uncemented hip joint prosthesis system....
The cemented hip joint prosthesis system....
The cemented hip joint prosthesis system....
The Quatroloc primary hip system offers 35 primary stems to fit almost all femurs for primary hip arthroplasty....
Medicine Products: